Vasculitis and Giant Cell Arteritis News

The diagnosis of giant cell arteritis may be aided by the use of fluorodeoxyglucose positron emission tomography/CT in patients who have not been exposed to glucocorticoids, according to recently published research.

The response by patients with anti-neutrophil cytoplasmic antibody-associated vasculitis to treatment with either cyclophosphamide or Rituxan may be indicated by the size of granulocytes prior to treatment, according to the results of an analysis by researchers at the Institute for Computational Science at University of California, San Francisco.

SLACK Incorporated, publisher of Healio.com, is set to expand its series of web-first news magazines delivering unique peer-tested content. Healio Rheumatology will compile the most-read content from Healio.com based on website metrics, and distribute it in a print news magazine reaching 6,100 U.S. physicians, including the universe of U.S. rheumatologists.

Patients with primary Sjögren’s syndrome were at higher risk for hospitalization in the presence of hepatic involvement, vasculitis and high disease activity, according to recently published research.

Around 78% of patients with large vessel vasculitis may have antibodies to 14-3-3 proteins, the presence of which may serve as a novel biomarker for the disease, according to researchers at the Cleveland Clinic and University Hospitals Case Medical Center.

After a patient is hospitalized, diagnosis codes for rheumatoid arthritis and giant cell arteritis are often omitted, which could yield inaccurate results when research is conducted based on the use of medical codes, according to research from the Mayo Clinic.

The use of positron emission tomography may be helpful in making the diagnosis of large vessel vasculitis, according to data presented recently.

Xoma today announced gevokizumab failed to meet its primary endpoints in a phase 3 trial in patients with uveitis caused by Behçet’s disease, according to a company press release.

Patients with familial Mediterranean fever may have comorbid rheumatic diseases that are not prevented with adequate colchicine therapy, according to study findings.

Researchers at the European League Against Rheumatism Annual European Congress of Rheumatology presented real-world clinical practice data on the use of Rituxan in patients with ANCA-associated vasculitis at a clinical setting in Greece.